Form 4: IOVANCE COO Igor Bilinsky Reports RSU Vesting and Tax Withholding

IOVANCE Biotherapeutics Chief Operating Officer Igor Bilinsky reported the vesting of restricted stock units and subsequent share withholding for tax obligations on September 2, 2025.

Summary

• Igor Bilinsky, Chief Operating Officer of IOVANCE Biotherapeutics, reported transactions related to his beneficial ownership.
• On September 2, 2025, 12,306 shares of common stock were acquired due to the vesting of restricted stock units (RSUs).
• Following this acquisition, Bilinsky beneficially owned 105,939 shares of common stock directly.
• Concurrently, 6,250 shares of common stock were disposed of at a price of $2.19 per share to satisfy mandatory tax withholding requirements upon RSU vesting. This was not an open market sale.
• After the tax withholding, Bilinsky's direct beneficial ownership of common stock was 99,689 shares.
• Derivative security transactions also occurred on September 2, 2025, involving the vesting of 3,516 and 8,790 Restricted Stock Units, respectively.
• These RSUs represent a contingent right to receive one share of common stock each, with a conversion price of $0.00.
• Following these derivative transactions, Bilinsky holds 7,033 remaining RSUs from a March 2, 2023 grant and 52,738 remaining RSUs from a March 1, 2024 grant.

Sentiment

Score: 5

Explanation: The filing is a routine Form 4 reporting scheduled RSU vesting and tax withholding, which are expected events and do not inherently indicate positive or negative operational performance or strategic shifts. It is neutral in sentiment.

Positives

• The vesting of Restricted Stock Units (RSUs) represents a realization of compensation for the Chief Operating Officer, indicating continued alignment of management incentives with shareholder value.
• The acquisition of 12,306 shares of common stock through RSU vesting increases the COO's direct equity stake in the company, demonstrating ongoing commitment.

Negatives

• 6,250 shares were disposed of to cover mandatory tax withholding, which slightly reduces the COO's direct share count, though this is a standard and expected event for RSU vesting.

Future Outlook

Remaining Restricted Stock Units (RSUs) held by Igor Bilinsky are scheduled to vest in equal quarterly installments, indicating a structured long-term compensation plan.

Industry Context

This filing represents a routine insider transaction related to executive compensation, common across the biotechnology industry where equity-based incentives like Restricted Stock Units are a standard component of executive pay packages to align management interests with long-term company performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of equity compensation and the subsequent withholding of shares for tax purposes upon vesting are standard practices in the biotechnology and broader corporate sectors.
• Companies like Amgen (AMGN), Gilead Sciences (GILD), and Moderna (MRNA) frequently utilize similar equity compensation structures for their executives, with Form 4 filings routinely disclosing such vesting and tax-related transactions.
• The reported transactions are consistent with typical executive compensation realization events.

Stakeholder Impact

• Shareholders: Minimal direct impact, as it reflects routine executive compensation. It confirms the COO's continued equity stake, aligning interests.
• Employees: No direct impact on general employees.
• Management: The vesting represents a realization of compensation for the COO.

Next Steps

• Remaining Restricted Stock Units (RSUs) will continue to vest in equal quarterly installments.

Key Dates

Keywords

IOVANCE Biotherapeutics, IOVA, Igor Bilinsky, Chief Operating Officer, Form 4, SEC filing, Restricted Stock Units, RSU vesting, stock ownership, insider transaction, equity compensation, tax withholding